Bacterial endotoxin (lipopolysaccharide, LPS) (LPS)

Bacterial endotoxin, also known as lipopolysaccharide (LPS), is a major component of the outer membrane of Gram-negative bacteria and is the primary mediator responsible for septic shock in humans. It acts as a potent inducer of the innate immune response by interacting with host proteins such as lipopolysaccharide-binding protein (LBP) and CD14, leading to strong inflammatory reactions that can result in sepsis or septic shock if not controlled[4][9]. Therapeutic strategies for endotoxin neutralization focus on molecules that bind to LPS and block its interaction with host receptors. These include natural proteins like Limulus anti-LPS factor (LALF), synthetic peptides derived from antimicrobial proteins such as cathelicidins or lactoferrin, small molecule polyamines called lipopolyamines, monoclonal antibodies targeting LPS epitopes, aptamers designed for high-affinity binding to toxins, and cell-membrane-coated nanoparticles that sequester toxins away from target cells[1][2][3][4][6]. Drugs like polymyxin B are used clinically due to their ability to bind lipid A—the toxic moiety within LPS—and neutralize its effects; however, these agents may have toxicity concerns at higher doses. While "bacterial endotoxin neutralization" describes an important therapeutic strategy rather than a single molecular target or receptor itself—making it an incorrect entry under strict definitions—it remains a critical area in infectious disease pharmacology aimed at mitigating the harmful effects caused by Gram-negative bacterial infections[9]. Note: The term "bacterial endotoxin neutralization" does not refer to a specific molecule or receptor but rather describes various mechanisms and agents developed for this purpose. Therefore, *is_incorrect* is set to true because it does not represent a canonical drug target but instead refers broadly to an intervention strategy.

Other names

EndotoxinLipopolysaccharideGram-negative bacterial endotoxin

Binding and neutralization of LPS to prevent activation of host immune signaling pathways